1. ALLA AKTIER
  2. NYHETER
  3. CELLAVISION

CellaVision

Nyheter CellaVision Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Underlying demand unchanged but external challenges persist

MAR

Organic sales growth:
Q4, 2022: -17% (25)

EBITDA margin:
Q4, 2022: 32% (37)

Summary, October 1-December 31, 2022

  • Net sales decreased by 7% to SEK 152 m (164).
  • Sales decreased organically by 17% (25), currency effect 10%.
  • EBITDA amounted to SEK 48 m (60).
  • EBITDA margin amounted to 32% (37).
  • Profit before tax amounted to SEK 40 m (51).
  • Earnings per share before and after dilution amounted to SEK 1.35 (1.67).
  • Cash flow from operating activities amounted to SEK 28 m (46).
  • The Board of Directors proposes an increased dividend to SEK 2.25 per share for 2022 (2.00).

Contact

Adele Horn
Corporate Communications & Investor Relations
Direct: + 46 46 460 26 04
Mobile: + 46 72 206 50 88
www.cellavision.com
adele.horn@cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 16 local market support organizations covering more than 40 countries. In 2021, sales were SEK 566 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-07 07:20 CET.

Attachments

Year End Report Q4 2022

Datum 2023-02-07, kl 07:20
Källa MFN
Bifogade filer
Year End Report Q4 2022